# A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer

> **NCT05968599** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 2731 (actual)

## Conditions studied

- Prostatic Neoplasms, Castration-Resistant

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** Abiraterone acetate

## Key facts

- **NCT ID:** NCT05968599
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-24
- **Primary completion:** 2025-02-14
- **Final completion:** 2025-02-14
- **Target enrollment:** 2731 (ACTUAL)
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05968599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05968599, "A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05968599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*